Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
Location: United States, Washington, Seattle
Employees: 201-500
Phone: +1 206-676-5000
Founded date: 1994
Investors 5
| Date | Name | Website |
| - | Puget Soun... | pugetsound... |
| 13.07.2025 | Foresite C... | foresiteca... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | CRG | crglp.com |
| - | SpringRock... | springrock... |
Mentions in press and media 5
| Date | Title | Description |
| 03.12.2021 | OMEROS ANNOUNCES AGREEMENT TO SELL OMIDRIA FRANCHISE TO RAYNER SURGICAL IN A TRANSACTION VALUED IN EXCESS OF $1 BILLION | SEATTLE - Omeros Corporation (Nasdaq: OMER) announced that it has entered into a definitive agreement for the sale of OMIDRIA to Rayner Surgical Group Limited. Expected to close on or before December 31, 2021, the transaction includes an up... |
| 02.12.2021 | Omeros : Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion - Form 8-K | Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion -- Transaction to Lock in Ongoing Revenue Stream for Omeros and Focus the Company on its Complement Franchise of MASP-2... |
| 02.12.2021 | Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion | Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a definitive agreement for the sale of OMIDRIA to Rayner Surgical Group Limited. Expected to close on or before December 31, 2021, the transaction includes an upfron... |
| 31.10.2014 | Tetra Discovery Lands Funding, Plans Alzheimer’s Drug Trial in 2015 | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Grand Rapids, MI-based biotech startup Tetra Discovery has been in the news a lot lately. This week, the Michigan Pre-Seed Fund 2.0 announced that Tetra Discovery was the reci... |
| 06.10.2008 | ChemoCentryx raises $50M, eyes bleak IPO landscape for biotech | ChemoCentryx Inc., a biotech company that develops drugs to treat immune system ailments, got a $50 million payday from partner and major shareholder GlaxoSmithKline PLC in August. The plan last November was to raise $57.5 million through a... |